TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for TuHURA Biosciences in a report issued on Monday, June 30th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.57) for the year, down from their prior forecast of ($0.56). HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for TuHURA Biosciences' Q4 2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.53) EPS.
HURA has been the subject of a number of other reports. Wall Street Zen downgraded shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Brookline Capital Management raised shares of TuHURA Biosciences to a "strong-buy" rating in a research report on Monday, June 23rd. One analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $12.67.
Get Our Latest Stock Analysis on TuHURA Biosciences
TuHURA Biosciences Stock Down 5.4%
HURA traded down $0.14 during trading on Wednesday, reaching $2.47. 603,783 shares of the company's stock were exchanged, compared to its average volume of 264,632. The business has a 50 day moving average price of $3.13 and a 200 day moving average price of $3.59. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02).
Institutional Investors Weigh In On TuHURA Biosciences
Hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. acquired a new position in TuHURA Biosciences in the fourth quarter valued at about $61,000. Accent Capital Management LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $29,000. Geode Capital Management LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $1,084,000. Hurlow Wealth Management Group Inc. acquired a new position in shares of TuHURA Biosciences in the 4th quarter worth approximately $170,000. Finally, TT Capital Management LLC bought a new stake in TuHURA Biosciences during the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 0.62% of the company's stock.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
